BioGaia Valuation
Is BIOG B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOG B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOG B (SEK103.9) is trading above our estimate of fair value (SEK99.09)
Significantly Below Fair Value: BIOG B is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOG B?
Key metric: As BIOG B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BIOG B's PE Ratio? | |
|---|---|
| PE Ratio | 31.2x |
| Earnings | SEK 336.82m |
| Market Cap | SEK 10.56b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7x |
| Enterprise Value/EBITDA | 20x |
| PEG Ratio | 1.9x |
Price to Earnings Ratio vs Peers
How does BIOG B's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 61.1x | ||
SOBI Swedish Orphan Biovitrum | 29.3x | 20.2% | SEK 102.4b |
BIOT Biotage | 46.6x | 19.5% | SEK 12.1b |
MCAP MedCap | 33.3x | n/a | SEK 7.8b |
ALIF B AddLife | 135.3x | 52.0% | SEK 16.1b |
BIOG B BioGaia | 31.2x | 16.6% | SEK 10.6b |
Price-To-Earnings vs Peers: BIOG B is good value based on its Price-To-Earnings Ratio (31.2x) compared to the peer average (61.1x).
Price to Earnings Ratio vs Industry
How does BIOG B's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BIOG B is expensive based on its Price-To-Earnings Ratio (31.2x) compared to the European Biotechs industry average (26.8x).
Price to Earnings Ratio vs Fair Ratio
What is BIOG B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.2x |
| Fair PE Ratio | 40.7x |
Price-To-Earnings vs Fair Ratio: BIOG B is good value based on its Price-To-Earnings Ratio (31.2x) compared to the estimated Fair Price-To-Earnings Ratio (40.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AstraZeneca
UK£154.7b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£1,392.50
7D
-1.0%
1Y
4.7%
Swedish Orphan Biovitrum
SEK 102.4b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 298.20
7D
-9.1%
1Y
23.3%
Ascelia Pharma
SEK 252.2m
A biotech company, focuses on orphan oncology treatments in Sweden.
ACE
SEK 2.63
7D
-0.9%
1Y
-9.3%